Blanda Stammen

Maraviroc (UK-427,857), a Potent, Orally Bioavailable, and Selective Small-Molecule Inhibitor of Chemokine Receptor CCR5 with Broad-Spectrum Anti-Human Immunodeficiency Virus Type 1 Activity

Patrick Dorr, Mike Westby, Susan Dobbs et al. · Antimicrobial Agents and Chemotherapy · 2005 · 1.1K citations · Full text

Standard Deviations, Immunology, Pharmacotherapy +19

Small Molecules Targeting Hepatitis C Virus-Encoded NS5A Cause Subcellular Redistribution of Their Target: Insights into Compound Modes of Action

Paul Targett‐Adams, Emily J. S. Graham, Jenny Middleton et al. · Journal of Virology · 2011 · 119 citations

Immunology, Molecular Biology, Lipid Droplets +20

Palladium‐Catalysed Intramolecular Cyclisations of Olefinic Propargylic Carbonates and application to the diastereoselective synthesis of enantiomerically pure (−)‐α‐thujone

Wolfgang Oppolzer, Austen D. Pimm, Blanda Stammen et al. · Helvetica Chimica Acta · 1997 · 93 citations · Full text

Engineering, Natural Sciences, Diversity-oriented Synthesis +13

Overcoming HERG affinity in the discovery of the CCR5 antagonist maraviroc

David A. Price, Duncan Armour, Marcel de Groot et al. · Bioorganic & Medicinal Chemistry Letters · 2006 · 76 citations · Full text

Molecular Pharmacology, Ccr5 Antagonist Maraviroc, Medicine +5

Initial synthesis of UK-427,857 (Maraviroc)

David A. Price, Simon Gayton, Matthew D. Selby et al. · Tetrahedron Letters · 2005 · 50 citations

Organic Chemistry, Combinatorial Chemistry, Pharmacology +1